Clinical trials: Placebo Response
Osteoarthritis, Knee
Study of SI000413 in Knee Osteoarthritis Patients
The purpose of this study is to evaluate efficacy and safety of SI000413 in patients with knee osteoarthritis by orally administration and to determine optimal dose.
- Trial name
- NCT01525758
- Testing
- SI000413, microcrystalline cellulose
- Where
- 3 sites in South Korea
- Volunteers
- 152 people
- Sponsor
- Dong-A Pharmaceutical Co., Ltd.
Immune Response
Study to Evaluate the Ability of Sublingual MV130 to Induce the Expression of Trained Immunity in Peripheral Blood Cells
A mechanistic clinical trial with the aim to evaluate whether MV130 can induce the expression of a particular immune response (trained immunity) in peripheral blood cells.
- Trial name
- NCT05208060
- Testing
- MV130
- Where
- Spain
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Inmunotek S.L.
Sepsis
Effect of Multiple Dose Levels of SRT2379 on Endotoxin-Induced Inflammation
SRT2379 is a potent small molecule activator of SIRT1 that has been found to inhibit systemic inflammation induced by intravenous injection of lipopolysaccharide (LPS) in mice.
- Trial name
- NCT01416376
- Testing
- SRT2379
- Where
- Netherlands
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Sirtris, a GSK Company
Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms
Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
CLARITY (Clinical Assessment of Response in the Treatment of Depression with Daytime Sleepiness Using Solriamfetol) is a Phase 3, double-blind, placebo-controlled, multicenter randomized withdrawal trial in patients with major…
- Trial name
- CLARITY (NCT07484217)
- Testing
- Solriamfetol 150 MG
- Where
- 40 sites in United States
- Volunteers
- 508 people
- Sponsor
- Axsome Therapeutics, Inc.
Hodgkin's Lymphoma
A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin's Lymphoma (HL)
The primary objective was to provide drug to ongoing patients who were receiving panobinostat and to characterize the safety and tolerability of panobinostat in patients with HL after achieving a complete response following…
- Trial name
- PATH (NCT01034163)
- Testing
- Panobinostat
- Where
- 35 sites in United States, Australia and 12 more
- Volunteers
- 41 people
- Sponsor
- Novartis Pharmaceuticals
Tuberculosis
Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in Healthy Volunteers
This randomized, placebo-controlled, double-blind, safety and dose-finding Phase Ia trial will evaluate four dose levels of the BNT164 investigational vaccines (BNT164a1 and BNT164b1) to select a safe and tolerable dose in a…
- Trial name
- NCT05537038
- Testing
- BNT164a1, BNT164b1
- Where
- 3 sites in Germany
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Parkinson's Disease (PD)
Effect of Two Multiple-dose Regimens of BIA 3-202 on the Pharmacokinetics and Motor Response of Levodopa, and on the Erythrocyte Comt Activity in Parkinson's Disease Patients
The purpose of this study is to determine the effect of two different multiple-dose regimens of nebicapone in comparison to placebo and entacapone 200 mg on the pharmacokinetics of levodopa in Parkinson's Disease (PD) patients.
- Trial name
- NCT02834507
- Testing
- BIA 3-202, Comtan®, Sinemet®
- Volunteers
- 19 people
- Sponsor
- Bial - Portela C S.A.
Migraine With or Without Aura
Eletriptan for the Treatment of Migraine in Patients With Previous Poor Response or Tolerance to Oral Sumatriptan
To determine the tolerability and efficacy of eletriptan in patients who had discontinued oral sumatriptan due to lack of efficacy or intolerable adverse events (AEs) during previous clinical treatment (not a controlled trial).
- Trial name
- NCT01989936
- Testing
- Eletriptan 40 mg, Eletriptan 80 mg
- Where
- 43 sites in Denmark, Finland and 3 more
- Volunteers
- 446 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Chronic Spontaneous Urticaria
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up
The purpose of this trial is: 1. to assess the efficacy, pharmacokinetics, and safety of remibrutinib vs. placebo in adolescents from 12 to < 18 years of age suffering from chronic spontaneous urticaria inadequately controlled by…
- Trial name
- NCT05677451
- Testing
- LOU064 (blinded)
- Where
- 49 sites in United States, Argentina and 15 more
- Volunteers
- 100 people
- Sponsor
- Novartis Pharmaceuticals
Attention Deficit Disorder With Hyperactivity
A Study of the Effectiveness and Safety of Prolonged-release Methylphenidate Hydrochloride in Adult Patients With Attention Deficit/Hyperactivity Disorder.
The purpose of this study is to evaluate the effectiveness and safety of three doses of prolonged-release methylphenidate (a central nervous system (CNS) stimulant) in adult patients with attention deficit/hyperactivity disorder…
- Trial name
- NCT00246220
- Testing
- methylphenidate hydrochloride
- Volunteers
- 402 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Stress, Anxiety
Examining the Effects of CXB722 in Neuroendocrine Stress Response in Healthy Males
The purpose of this study is to assess the effects of CXB722 on neuroendocrine stress response and subjective reports related to mood and stress during and after experimentally induced stress among healthy young males.
- Trial name
- CXB722-100 (NCT00814931)
- Testing
- CXB722
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- CeNeRx BioPharma Inc.
Lung Cancer
ZD6474 in Treating Patients With Small Cell Lung Cancer
RATIONALE: ZD6474 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. ZD6474 may also stop the growth of small cell lung cancer by blocking blood flow to the tumor.
- Trial name
- NCT00066313
- Testing
- vandetanib, adjuvant therapy
- Where
- 21 sites in Canada
- Sponsor
- Genzyme, a Sanofi Company
Atopic Dermatitis
Study of Dupilumab and Immune Responses in Adults With Atopic Dermatitis (AD)
This was a 32-week, randomized, double-blind, placebo-controlled, parallel-group study assessing immunization responses to vaccination in adults with moderate to severe atopic dermatitis who are treated with subcutaneous…
- Trial name
- NCT02210780
- Testing
- Dupilumab
- Where
- 42 sites in United States
- Volunteers
- 194 people
- Sponsor
- Regeneron Pharmaceuticals
Treatment Resistant Depression, Major Depressive Disorder
Mechanistic Evaluation of Response in TRD (MERIT)
To evaluate the relapse prevention of AXS-05 relative to placebo in subjects with treatment resistant depression (TRD). This is a randomized, double-blind, placebo-controlled study to evaluate AXS-05 compared to placebo in…
- Trial name
- MERIT (NCT04608396)
- Testing
- AXS-05
- Where
- 20 sites in United States
- Volunteers
- 44 people
- Sponsor
- Axsome Therapeutics, Inc.
Mild to Moderate Bronchial Asthma
Safety and Efficacy of SA09012 in Asthma
Clinical Study to Evaluate the Efficacy, Dose-response and Safety of SA09012 in Bronchial Asthma Patients
- Trial name
- NCT01740986
- Testing
- SA09012 Low dose, SA09012 High dose
- Where
- 14 sites in South Korea
- Volunteers
- 225 people
- Sponsor
- SamA Pharmaceutical Co., Ltd
Metabolism and Nutrition Disorder, Obesity
A Two Part Trial Investigating an Anti-obesity Drug in Overweight/Obese Male and Female Healthy Volunteers
This trial is conducted in the United States of America (USA). The aim of this trial is to investigate the safety, tolerability, efficacy and pharmacokinetics (the rate at which the trial drug is eliminated from the body) of NNC…
- Trial name
- NCT01044108
- Testing
- NNC 0070-0002-0453, '2-0453
- Where
- United States
- Volunteers
- 117 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Seasonal Allergic Rhinitis
A Study to Determine the Capacity of VAK694 When Combined With Allergen Immunotherapy to Bring About Specific Immune Tolerance
The purpose of the study is to determine whether VAK694 when combined with subcutaneous immunotherapy leads to long term immune tolerance to allergen in individuals with seasonal allergic rhinitis.
- Trial name
- NCT01018693
- Testing
- VAK694; Alutard Avanz SQ
- Where
- United Kingdom
- Volunteers
- 37 people
- Sponsor
- Novartis Pharmaceuticals
Rheumatoid Arthritis
Abatacept Post-marketing Clinical Study in Japan
The purpose of this study is to compare the clinical efficacy including joint damage progression and safety of Abatacept plus Methotrexate (MTX) to placebo plus MTX.
- Trial name
- NCT01758198
- Testing
- Abatacept, Methotrexate
- Where
- 74 sites in Japan
- Volunteers
- 405 people
- Sponsor
- Bristol-Myers Squibb
Asthma
Study Of Fluticasone Propionate/Salmeterol In Asthmatic Subjects
The aim of the present study is to investigate whether the effects of salmeterol in combination with fluticasone propionate on blood markers of airway inflammation are maintained after chronic dosing and whether the effect is…
- Trial name
- NCT00517634
- Testing
- FP, SFC
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 23 people
- Sponsor
- GlaxoSmithKline
Venous Leg Ulcer
Dose-response Relationship Study of S42909 on Leg Ulcer Healing
Dose-response relationship study of S42909 on leg ulcer healing after oral repeated administration in patients with active venous leg ulcer.
- Trial name
- NCT03077165
- Testing
- S42909 100 mg, S42909 200 mg, S42909 400 mg
- Where
- 80 sites in United States, Argentina and 9 more
- Volunteers
- 121 people
- Sponsor
- Ilkos Therapeutic Inc.